Clinical Study “Relaxin-2 for Patients with chronic symptomatic Heart Failure”

2025-03-14T12:14:15+01:0011.2020|

Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin-2 in patients with heart failure. Title of the study: Synthetic human relaxin-2 for patients with chronic symptomatic heart failure with preserved and mildly reduced ejection fraction (HFpEF, HFmrEF) and high fibrosis risk: A multi-center, double-blind, randomized, parallel-arm phase II [...]

Relaxera and University of Pittsburgh announce research cooperation

2022-12-16T17:54:26+01:0003.2018|

As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, among others, be on relaxin’s effects towards isoform expression and [...]

Go to Top